Literature DB >> 33024991

Risk factors in multiple myeloma: is it time for a revision?

Jill Corre1,2, Nikhil C Munshi3,4, Hervé Avet-Loiseau1,2.   

Abstract

Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drug combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.

Entities:  

Mesh：

Year:  2021        PMID： 33024991      PMCID： PMC7808011          DOI： 10.1182/blood.2019004309

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


  40 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.

Authors:  Sarah Goldman-Mazur; Artur Jurczyszyn; Jorge J Castillo; Anna Waszczuk-Gajda; Norbert Grząśko; Jakub Radocha; Max Bittrich; K Martin Kortüm; Alessandro Gozzetti; Lidia Usnarska-Zubkiewicz; Julio Davila Valls; David S Jayabalan; Ruben Niesvizky; Julia Kelman; Daniel Coriu; Laura Rosiñol; Łukasz Szukalski; Veronica González-Calle; Maria V Mateos; Krzysztof Jamroziak; Iwona Hus; Irit Avivi; Yael Cohen; Anna Suska; Aimee Chappell; Deepu Madduri; Saurabh Chhabra; Ariel Kleman; Parameswaran Hari; Michel Delforge; Paweł Robak; Massimo Gentile; Izabela Kozłowska; Stuart L Goldberg; Jacek Czepiel; Rebecca Silbermann; Adam J Olszewski; Peter Barth; Gabor Mikala; Chor S Chim; Monika Długosz-Danecka; Sebastian Grosicki; David H Vesole
Journal:  Am J Hematol       Date:  2020-02-29       Impact factor: 10.047

3.  Extramedullary involvement in multiple myeloma.

Authors:  Joan Bladé; Carlos Fernández de Larrea; Laura Rosiñol
Journal:  Haematologica       Date:  2012-11       Impact factor: 9.941

4.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

5.  High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Authors:  Anjan Thakurta; Maria Ortiz; Pedro Blecua; Fadi Towfic; Jill Corre; Natalya V Serbina; Erin Flynt; Zhinuan Yu; Zhihong Yang; Antonio Palumbo; Meletios A Dimopoulos; Norma C Gutierrez; Hartmut Goldschmidt; Pieter Sonneveld; Herve Avet-Loiseau
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

Review 6.  Genomics of Multiple Myeloma.

Authors:  Sebastien Robiou du Pont; Alice Cleynen; Charlotte Fontan; Michel Attal; Nikhil Munshi; Jill Corre; Hervé Avet-Loiseau
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

7.  Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Authors:  Aurore Perrot; Valérie Lauwers-Cances; Elodie Tournay; Cyrille Hulin; Marie-Lorraine Chretien; Bruno Royer; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Jean Fontan; Laurent Voillat; Hélène Demarquette; Philippe Collet; Philippe Rodon; Claudine Sohn; François Lifermann; Frédérique Orsini-Piocelle; Valentine Richez; Mohamad Mohty; Margaret Macro; Stéphane Minvielle; Philippe Moreau; Xavier Leleu; Thierry Facon; Michel Attal; Hervé Avet-Loiseau; Jill Corre
Journal:  J Clin Oncol       Date:  2019-05-15       Impact factor: 44.544

8.  The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.

Authors:  F Dicker; H Herholz; S Schnittger; A Nakao; N Patten; L Wu; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

9.  The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.

Authors:  Charlotte Pawlyn; David Cairns; Martin Kaiser; Alina Striha; John Jones; Vallari Shah; Matthew Jenner; Mark Drayson; Roger Owen; Walter Gregory; Gordon Cook; Gareth Morgan; Graham Jackson; Faith Davies
Journal:  Leukemia       Date:  2019-10-14       Impact factor: 11.528

10.  del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.

Authors:  Jill Corre; Aurore Perrot; Denis Caillot; Karim Belhadj; Cyrille Hulin; Xavier Leleu; Mohamad Mohty; Thierry Facon; Laure Buisson; Laura Do Souto; Romain Lannes; Stephanie Dufrechou; Naïs Prade; Frederique Orsini-Piocelle; Laurent Voillat; Arnaud Jaccard; Lionel Karlin; Margaret Macro; Sabine Brechignac; Mamoun Dib; Laurence Sanhes; Jean Fontan; Lauriane Clement-Filliatre; Jean-Pierre Marolleau; Stephane Minvielle; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113
View more
  11 in total

1.  High-risk multiple myeloma: how to treat at diagnosis and relapse?

Authors:  María-Victoria Mateos; Borja Puertas Martínez; Verónica González-Calle
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

Authors:  Richard LeBlanc; Imran Ahmad; Rafik Terra; Jean-Samuel Boudreault; David Ogez; Kristopher Lamore; Jean-Sébastien Delisle; Nadia Bambace; Léa Bernard; Sandra Cohen; Thomas Kiss; Silvy Lachance; Séverine Landais; Émilie Lemieux-Blanchard; Guy Sauvageau; Michael Sebag; Denis Claude Roy; Jean Roy
Journal:  Bone Marrow Transplant       Date:  2021-11-29       Impact factor: 5.483

3.  Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling.

Authors:  Qiang-Sheng Wang; Qi-Qin Shi; Ye Meng; Meng-Ping Chen; Jian Hou
Journal:  Front Genet       Date:  2022-05-26       Impact factor: 4.772

4.  The EHA Research Roadmap: Malignant Lymphoid Diseases.

Authors:  Martin Dreyling; Marc André; Nicola Gökbuget; Hervé Tilly; Mats Jerkeman; John Gribben; Andrés Ferreri; Pierre Morel; Stephan Stilgenbauer; Christopher Fox; José Maria Ribera; Sonja Zweegman; Igor Aurer; Csaba Bödör; Birgit Burkhardt; Christian Buske; Maria Dollores Caballero; Elias Campo; Bjoern Chapuy; Andrew Davies; Laurence de Leval; Jeanette Doorduijn; Massimo Federico; Philippe Gaulard; Francesca Gay; Paolo Ghia; Kirsten Grønbæk; Hartmut Goldschmidt; Marie-Jose Kersten; Barbara Kiesewetter; Judith Landman-Parker; Steven Le Gouill; Georg Lenz; Sirpa Leppä; Armando Lopez-Guillermo; Elizabeth Macintyre; Maria Victoria Mateos Mantega; Philippe Moreau; Carol Moreno; Bertrand Nadel; Jessica Okosun; Roger Owen; Sarka Pospisilova; Christiane Pott; Tadeusz Robak; Michelle Spina; Kostas Stamatopoulos; Jan Stary; Karin Tarte; Allessandra Tedeschi; Catherine Thieblemont; Ralf Ulrich Trappe; Lorenz H Trümper; Gilles Salles
Journal:  Hemasphere       Date:  2022-05-19

Review 5.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 6.  Genetic Predictors of Mortality in Patients with Multiple Myeloma.

Authors:  Hamza Hassan; Raphael Szalat
Journal:  Appl Clin Genet       Date:  2021-04-29

7.  The Apparent Diffusion Coefficient of Diffusion-Weighted Whole-Body Magnetic Resonance Imaging Affects the Survival of Multiple Myeloma Independently.

Authors:  Bei Zhang; Bingyang Bian; Yanjiao Zhang; Li Zhang; Rongkui Zhang; Jiping Wang
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

8.  IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma.

Authors:  Meng Liu; Ying Zhang; Yunzhao Wu; Jin Jin; Yang Cao; Zhixiao Fang; Lou Geng; Li Yang; Miao Yu; Zhilei Bu; Yanjie Ji; Huizhuang Shan; Zhihui Zou; Ligen Liu; Yingying Wang; Youping Zhang; Yin Tong; Hanzhang Xu; Hu Lei; Wei Liu; Fenghou Gao; Yingli Wu
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

9.  The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

Authors:  Hoi Ki Karen Tang; Chi Yeung Fung; Gareth J Morgan; Shaji Kumar; Lisa Siu; Ho Wan Alvin Ip; Sze Fai Yip; Ka Ngai Harry Lau; Chi Kuen Lau; Harold Lee; Kwan Hung Leung; Bonnie Kho; Howard Wong; Cheong Ngai; Yu Yan Hwang; Joycelyn Sim; Yok Lam Kwong; Chor Sang Chim
Journal:  Ther Adv Hematol       Date:  2022-04-18

Review 10.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.